Severity Levels of Haemophilia: From Mild to Severe

Not all cases of haemophilia look the same. One person may bleed heavily only after a major surgery and have gone years without a diagnosis, while another may bleed spontaneously into their joints several times a week without any injury at all. This striking difference comes down to one key factor – quite literally. The severity of haemophilia is directly determined by how much functional clotting factor is present in a person’s blood, and this single measurement shapes everything from symptoms to diagnosis to long-term health outcomes.

How clotting factor levels determine severity 🔗

In a healthy individual, the normal range of clotting factor activity – as defined by the World Federation of Haemophilia – falls between 50% and 150% (expressed in international units per millilitre of blood, or IU/ml). This range allows the blood to clot efficiently in response to injury. In haemophilia, either Factor VIII (in Haemophilia A) or Factor IX (in Haemophilia B) is deficient or entirely absent, reducing this capacity significantly.

The lower the clotting factor level, the more severe and more frequent the bleeding. Based on this, the International Society on Thrombosis and Haemostasis (ISTH) defined three formal severity categories in 2001: mild, moderate, and severe. These categories remain the international standard for classifying and managing the condition today.

Mild haemophilia (factor level: 5%-40%) 🔗

People with mild haemophilia typically experience bleeding only after serious injury, trauma, or surgery. Day-to-day activities rarely trigger a bleeding episode, and many individuals with this form of the condition go through childhood – and even much of adulthood – without knowing they have it.

The condition is often identified only when a surgical procedure, a tooth extraction, or a significant injury leads to unexpectedly prolonged bleeding. In many cases, mild haemophilia is not diagnosed until an injury or dental procedure results in bleeding that is difficult to stop, which can come as a shock to both the patient and their clinician. Women with mild haemophilia may notice it through heavy menstrual periods or postpartum haemorrhage.

Approximately 25% of people living with haemophilia have the mild form of the disease. Because bleeding episodes are infrequent and often tied to specific events, this group can be significantly underdiagnosed – particularly in settings where routine clotting factor screening is not standard practice.

Moderate haemophilia (factor level: 1%-5%) 🔗

Moderate haemophilia occupies a clinically important middle ground. Those with moderate haemophilia have between 1% and 5% clotting factor activity in their blood and may bleed roughly once a month, often after minor injuries, small surgical procedures, or dental treatment. Unlike the mild form, prolonged bleeding here does not require a major trauma to occur.

A notable feature of moderate haemophilia is the risk of haemarthrosis (bleeding into the joints) and haematoma (bleeding into muscle tissue). These can occur with relatively minor trauma and, in some cases, spontaneously – without any identifiable cause. This distinguishes moderate haemophilia from the mild form and signals an increased burden on the musculoskeletal system over time.

It is worth noting that bleeding patterns are not always predictable. Some people with moderate haemophilia may bleed as much as, or more than, those with severe haemophilia, depending on individual genetic factors, the specific type of mutation involved, and other variables in the coagulation cascade. Around 15% of all people with haemophilia have the moderate form.

Severe haemophilia (factor level: less than 1%) 🔗

Severe haemophilia is the most clinically demanding category. With less than 1% measurable clotting factor, individuals with severe haemophilia bleed spontaneously – meaning bleeding occurs without any obvious injury or cause. Bleeding episodes can happen as often as once or twice a week, and they predominantly affect the muscles and joints.

Severe haemophilia accounts for approximately 60% of all haemophilia cases, making it the most common severity level seen in clinical settings. Most individuals with this form are diagnosed very early – often within the first year of life – following events such as prolonged bleeding after a heel-prick test, a difficult circumcision, or intracranial bleeding.

Joint damage: the long-term consequence of repeated bleeding 🔗

The most serious long-term complication of severe haemophilia is haemophilic arthropathy – irreversible joint damage caused by recurrent bleeding. In severe haemophilia, 90% of bleeding episodes involve the musculoskeletal system, and in 80% of those cases, the joints are specifically affected. The knees, elbows, and ankles are the most commonly targeted sites.

Each time blood enters a joint, it triggers an inflammatory response. Spontaneous joint bleeding and repeated haemarthroses lead to haemophilic arthropathy – a debilitating condition with a significant negative impact on mobility and quality of life. The process begins with synovitis (inflammation of the joint lining), progresses to cartilage degradation, and eventually results in permanent joint destruction if untreated.

Recurrent joint bleeding causes synovial proliferation and inflammation – known as haemophilic synovitis – which contributes to end-stage degeneration of the joint, leading to chronic pain and severely restricted movement. Without adequate treatment, joint bleeding can lead to complete destruction of the joint by early adulthood.

Muscle bleeds and haematomas 🔗

Beyond joints, muscle bleeding is a serious and painful complication in severe haemophilia. The deltoid, forearm flexors, quadriceps, and gastrocnemius-soleus complex are among the most commonly affected muscle groups. Large muscle haematomas can lead to compartment syndrome – a dangerous build-up of pressure within the muscle – if not treated promptly. In rare cases, untreated bleeds can lead to pseudotumours: slowly expanding masses that erode surrounding bone and soft tissue.

Why the same factor level doesn’t always mean the same experience 🔗

It would be tempting to treat severity classification as a perfectly predictive tool, but the clinical picture is more nuanced. The frequency and type of bleeds may vary significantly from one patient to another, even within the same severity category. For example, 10%-15% of individuals with severe haemophilia experience fewer spontaneous bleeding episodes than expected for their factor level.

This variation can arise from differences in the specific gene mutation responsible for the clotting factor deficiency, mutations in other coagulation-related genes, individual immune system differences, and physical activity levels. Researchers and clinicians have increasingly recognised that plasma clotting factor levels alone may not fully capture a patient’s bleeding phenotype, prompting ongoing discussion about whether severity classification should incorporate clinical bleeding history alongside laboratory measurements.

Diagnosis and the role of factor assays 🔗

Severity is established through a blood test called a clotting factor assay, which directly measures the activity level of the relevant clotting factor. Clotting factor tests – also called factor assays – determine the clotting activity of Factor VIII and Factor IX in the blood, enabling clinicians to confirm not only the type of haemophilia but also its severity level. This information is essential for planning treatment, setting prophylaxis schedules, and anticipating long-term risks.

Timing of diagnosis is closely tied to severity. Severe haemophilia often manifests in the first months of life, whereas mild or moderate haemophilia typically presents later in childhood or adolescence – often only after an injury or procedure exposes the underlying clotting deficiency. This delay in diagnosis for milder forms underscores the importance of family history screening and awareness.

Severity and its impact on quality of life 🔗

The progression from mild to severe haemophilia is not simply a matter of more frequent bleeding – it represents a fundamentally different lived experience. Individuals with mild haemophilia may live with few restrictions, while those with severe haemophilia manage a condition that, without treatment, affects their mobility, schooling, employment, and mental health from early childhood.

Haemophilic arthropathy is associated with increased pain, loss of employment, school absenteeism, and a reduction in physical wellbeing and quality of life. With modern prophylactic treatment – regular infusions of clotting factor concentrates to maintain baseline factor levels – many of the most severe outcomes can be prevented or delayed. However, access to such treatment remains deeply unequal globally, and in resource-limited settings, haemophilic arthropathy and disability remain significant realities for many living with severe haemophilia.

Understanding where a person falls on the severity spectrum is therefore not just a clinical classification – it is the foundation for every decision about their care, safety, and long-term wellbeing.

What do you think? If haemophilia severity is determined by a single blood measurement, should treatment plans also factor in a patient’s actual bleeding history and lifestyle? And given that mild haemophilia often goes undiagnosed for years, what changes in routine healthcare screening might help identify it sooner?

References

1. https://hemophilianewstoday.com/severity-levels-of-hemophilia/
2. https://www.cdc.gov/hemophilia/testing/index.html
3. https://co.bleeding.org/bleeding-disorders/types/hemophilia.html
4. https://www.bleeding.org/bleeding-disorders-a-z/types/hemophilia-a
5. https://www.bleedingdisorders.com/hemophilia-a/severity
6. https://www.ncbi.nlm.nih.gov/books/NBK470265/
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4207585/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC5532571/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC5556421/
10. https://now.aapmr.org/hemophilia-and-hemorrhagic-arthropathy/
11. https://www.sciencedirect.com/science/article/pii/S1538783623002477
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC8023018/